J&J reveals plans to appeal cancer drug court ruling

Johnson & Johnson (J&J) has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Medtech company sues over seven patents for incontinence products

13 May 2026 PureWick claims that two rivals infringed its external catheter and urine-management technology in their medical devices.

Americas

10x Genomics settles suit with rival and targets DNA sequencing startup

12 May 2026 The dominant player in the spatial biology market has sued a San Diego-based life sciences company over its genetic analysis technology, as another lawsuit in its patent litigation campaign approaches conclusion.

Americas

Trade secrets, AI and the new scrutiny of big damages awards

11 May 2026 Trade secret filings in the US reached an all-time high in 2025—particularly those relating to AI. Jeff Farrow of Michelman Robinson explains the principles that courts are increasingly applying, and how companies on both sides of the ‘v’ can prepare.

More features

Medtech company sues over seven patents for incontinence products

10x Genomics settles suit with rival and targets DNA sequencing startup

Trade secrets, AI and the new scrutiny of big damages awards

WATCH: Interview with Mythili Markowski, director at Regeneron

IP in the deal room: The risks that bite before, during and after closing

Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’

Five generations at work: How teams are bridging the gap

Kilpatrick adds tech patent litigator and China expert to Chicago office

J&J reveals plans to appeal cancer drug court ruling

More on this story

Editor's picks

Editor's picks

More features